<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36557244</PMID><DateRevised><Year>2022</Year><Month>12</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2218-1989</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Metabolites</Title><ISOAbbreviation>Metabolites</ISOAbbreviation></Journal><ArticleTitle>An NMR-Based Model to Investigate the Metabolic Phenoreversion of COVID-19 Patients throughout a Longitudinal Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1206</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/metabo12121206</ELocationID><Abstract><AbstractText>After SARS-CoV-2 infection, the molecular phenoreversion of the immunological response and its associated metabolic dysregulation are required for a full recovery of the patient. This process is patient-dependent due to the manifold possibilities induced by virus severity, its phylogenic evolution and the vaccination status of the population. We have here investigated the natural history of COVID-19 disease at the molecular level, characterizing the metabolic and immunological phenoreversion over time in large cohorts of hospitalized severe patients (n = 886) and non-hospitalized recovered patients that self-reported having passed the disease (n = 513). Non-hospitalized recovered patients do not show any metabolic fingerprint associated with the disease or immune alterations. Acute patients are characterized by the metabolic and lipidomic dysregulation that accompanies the exacerbated immunological response, resulting in a slow recovery time with a maximum probability of around 62 days. As a manifestation of the heterogeneity in the metabolic phenoreversion, age and severity become factors that modulate their normalization time which, in turn, correlates with changes in the atherogenesis-associated chemokine MCP-1. Our results are consistent with a model where the slow metabolic normalization in acute patients results in enhanced atherosclerotic risk, in line with the recent observation of an elevated number of cardiovascular episodes found in post-COVID-19 cohorts.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gil-Redondo</LastName><ForeName>Rub&#xe9;n</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3541-9085</Identifier><AffiliationInfo><Affiliation>Precision Medicine and Metabolism Laboratory, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conde</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-4372-081X</Identifier><AffiliationInfo><Affiliation>Precision Medicine and Metabolism Laboratory, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bizkarguenaga</LastName><ForeName>Maider</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0988-2006</Identifier><AffiliationInfo><Affiliation>Precision Medicine and Metabolism Laboratory, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruzzone</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Precision Medicine and Metabolism Laboratory, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La&#xed;n</LastName><ForeName>Ana</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7069-9126</Identifier><AffiliationInfo><Affiliation>Precision Medicine and Metabolism Laboratory, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez-Valle</LastName><ForeName>Beatriz</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-7197-3593</Identifier><AffiliationInfo><Affiliation>Precision Medicine and Metabolism Laboratory, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iriberri</LastName><ForeName>Milagros</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pneumology Department, Hospital Universitario de Cruces, 48903 Barakaldo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos-Acosta</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Medicine, UCM, Hematology Department, IML, IdISSC, Hospital Cl&#xed;nico San Carlos, 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anguita</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-1386-4943</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Medicine, UCM, Hematology Department, IML, IdISSC, Hospital Cl&#xed;nico San Carlos, 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arriaga Lariz</LastName><ForeName>Juan Ignacio</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Pneumology Department, Hospital Universitario de Basurto, 48013 Bilbao, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espa&#xf1;a Yandiola</LastName><ForeName>Pedro Pablo</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Pneumology Department, Hospital Universitario de Galdakao-Usansolo, 48960 Galdakao, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moran</LastName><ForeName>Miguel &#xc1;ngel</ForeName><Initials>M&#xc1;</Initials><AffiliationInfo><Affiliation>Bioaraba Health Research Institute, 01009 Vitoria-Gasteiz, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine Department, Infectious Diseases Section, Osakidetza Basque Health Service, Araba University Hospital, 01009 Vitoria-Gasteiz, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jim&#xe9;nez-Mercado</LastName><ForeName>Mario Ernesto</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Bioaraba Health Research Institute, 01009 Vitoria-Gasteiz, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emergency Department, Osakidetza Basque Health Service, Araba University Hospital, 01009 Vitoria-Gasteiz, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Egia-Mendikute</LastName><ForeName>Leire</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cancer Immunology and Immunotherapy Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seco</LastName><ForeName>Mar&#xed;a Luisa</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>OSARTEN Kooperatiba Elkartea, 20500 Arrasate-Mondrag&#xf3;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xe4;fer</LastName><ForeName>Hartmut</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Bruker Biospin GmbH, Silberstreifen, 76287 Rheinstetten, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cannet</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Bruker Biospin GmbH, Silberstreifen, 76287 Rheinstetten, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spraul</LastName><ForeName>Manfred</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bruker Biospin GmbH, Silberstreifen, 76287 Rheinstetten, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palaz&#xf3;n</LastName><ForeName>As&#xed;s</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7172-7229</Identifier><AffiliationInfo><Affiliation>Cancer Immunology and Immunotherapy Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ikerbasque, Basque Foundation for Science, 48015 Derio, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Embade</LastName><ForeName>Nieves</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-9878-3290</Identifier><AffiliationInfo><Affiliation>Precision Medicine and Metabolism Laboratory, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Shelly C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wist</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Australian National Phenome Center, and Center for Computational and Systems Medicine, Health Futures Institute, Murdoch University, Harry Perkins Building, Perth, WA 6150, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chemistry Department, Universidad del Valle, Cali 76001, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicholson</LastName><ForeName>Jeremy K</ForeName><Initials>JK</Initials><Identifier Source="ORCID">0000-0002-8123-8349</Identifier><AffiliationInfo><Affiliation>Australian National Phenome Center, and Center for Computational and Systems Medicine, Health Futures Institute, Murdoch University, Harry Perkins Building, Perth, WA 6150, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical School, Faculty of Health and Medical Sciences, University of Western Australia, Department of Endocrinology and Diabetes, Fiona Stanley Hospital, Perth, WA 6150, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Global Health Innovation, Faculty of Medicine, Imperial College London, Level 1, Faculty Building, South Kensington Campus, London SW7 2NA, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mato</LastName><ForeName>Jos&#xe9; M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0003-1264-3153</Identifier><AffiliationInfo><Affiliation>Precision Medicine and Metabolism Laboratory, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERehd, Instituto de Salud Carlos III, 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Millet</LastName><ForeName>Oscar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-8748-4105</Identifier><AffiliationInfo><Affiliation>Precision Medicine and Metabolism Laboratory, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), 48160 Derio, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERehd, Instituto de Salud Carlos III, 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>the SPRI I + D COVID-19 fund (Basque Government, bG-COVID-19)</Agency><Country/></Grant><Grant><Agency>BIOEF EITB Maratoia (BIO21/COV/037)</Agency><Country/></Grant><Grant><Agency>the European Research Council (ERC) (ERC-2018-StG 804236-NEXTGEN-IO), ISCiii DTS21/00094, RYC2018-024183-I; and PID2019-107956RA-I00</Agency><Country/></Grant><Grant><Agency>The Spinnaker Health Research Foundation, WA, The McCusker Foundation, WA, The Western Australian State Government</Agency><Country/></Grant><Grant><Agency>MRFF (grant number 2014349) for funding the Australian National Phenome Centre</Agency><Country/></Grant><Grant><Agency>the UK MRC</Agency><Country/></Grant><Grant><Agency>the Department of Jobs, Tourism, Science and Innovation, Government of Western Australian Premier's Fellowship</Agency><Country/></Grant><Grant><Agency>ARC Laureate Fellowship</Agency><Country/></Grant><Grant><Agency>Western Australian Covid Research Response team</Agency><Country/></Grant><Grant><Agency>Ministerio de Ciencia, Tecnolog&#xed;a e Innovaci&#xf3;n (Minciencias), Ministerio de Educaci&#xf3;n Nacional, Ministerio de Industria, Comercio y Turismo e ICETEX (792-2017) 2a Convocatoria Ecosistema Cient&#xed;fico - Colombia Cient&#xed;fica para la Financiaci&#xf3;n de Proye</Agency><Country/></Grant><Grant><Agency>World Bank and Vicerrector&#xed;a de Investigaciones, Pontificia Universidad Javeriana, Bogot&#xe1;, Co-lombia (contract no. FP44842 - 221-2018)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Metabolites</MedlineTA><NlmUniqueID>101578790</NlmUniqueID><ISSNLinking>2218-1989</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">atherosclerotic risk</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">lipidomics</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">metabolomics</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>23</Day><Hour>1</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36557244</ArticleId><ArticleId IdType="pmc">PMC9788519</ArticleId><ArticleId IdType="doi">10.3390/metabo12121206</ArticleId><ArticleId IdType="pii">metabo12121206</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mar&#xed;n-Corral J., Rodr&#xed;guez-Morat&#xf3; J., Gomez-Gomez A., Pascual-Guardia S., Mu&#xf1;oz-Berm&#xfa;dez R., Salazar-Degracia A., P&#xe9;rez-Ter&#xe1;n P., Restrepo M.I., Khymenets O., Haro N., et al. Metabolic Signatures Associated with Severity in Hospitalized COVID-19 Patients. Int. J. Mol. Sci. 2021;22:4794. doi: 10.3390/ijms22094794.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22094794</ArticleId><ArticleId IdType="pmc">PMC8124482</ArticleId><ArticleId IdType="pubmed">33946479</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruzzone C., Bizkarguenaga M., Gil-Redondo R., Diercks T., Arana E., Garc&#xed;a de Vicu&#xf1;a A., Seco M., Bosch A., Palaz&#xf3;n A., San Juan I., et al. SARS-CoV-2 Infection Dysregulates the Metabolomic and Lipidomic Profiles of Serum. iScience. 2020;23:101645. doi: 10.1016/j.isci.2020.101645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2020.101645</ArticleId><ArticleId IdType="pmc">PMC7534591</ArticleId><ArticleId IdType="pubmed">33043283</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser D.D., Slessarev M., Martin C.M., Daley M., Patel M.A., Miller M.R., Patterson E.K., O&#x2019;Gorman D.B., Gill S.E., Wishart D.S., et al. Metabolomics Profiling of Critically Ill Coronavirus Disease 2019 Patients: Identification of Diagnostic and Prognostic Biomarkers. Crit. Care Explor. 2020;2:e0272. doi: 10.1097/CCE.0000000000000272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCE.0000000000000272</ArticleId><ArticleId IdType="pmc">PMC7587450</ArticleId><ArticleId IdType="pubmed">33134953</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmelter F., F&#xf6;h B., Mallagaray A., Rahm&#xf6;ller J., Ehlers M., Lehrian S., von Kopylow V., K&#xfc;nsting I., Lixenfeld A.S., Martin E., et al. Metabolic and Lipidomic Markers Differentiate COVID-19 from Non-Hospitalized and Other Intensive Care Patients. Front. Mol. Biosci. 2021;8:1091. doi: 10.3389/fmolb.2021.737039.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2021.737039</ArticleId><ArticleId IdType="pmc">PMC8686182</ArticleId><ArticleId IdType="pubmed">34938772</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimhofer T., Lodge S., Whiley L., Gray N., Loo R.L., Lawler N.G., Nitschke P., Bong S.-H., Morrison D.L., Begum S., et al. Integrative Modeling of Quantitative Plasma Lipoprotein, Metabolic, and Amino Acid Data Reveals a Multiorgan Pathological Signature of SARS-CoV-2 Infection. J. Proteome Res. 2020;19:4442&#x2013;4454. doi: 10.1021/acs.jproteome.0c00519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.0c00519</ArticleId><ArticleId IdType="pubmed">32806897</ArticleId></ArticleIdList></Reference><Reference><Citation>San Juan I., Bruzzone C., Bizkarguenaga M., Bernardo-Seisdedos G., La&#xed;n A., Gil-Redondo R., Diercks T., Gil-Mart&#xed;nez J., Urquiza P., Arana E., et al. Abnormal Concentration of Porphyrins in Serum from COVID-19 Patients. Br. J. Haematol. 2020;190:e265. doi: 10.1111/bjh.17060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.17060</ArticleId><ArticleId IdType="pmc">PMC7436216</ArticleId><ArticleId IdType="pubmed">32745239</ArticleId></ArticleIdList></Reference><Reference><Citation>Caterino M., Costanzo M., Fedele R., Cevenini A., Gelzo M., Di Minno A., Andolfo I., Capasso M., Russo R., Annunziata A., et al. The Serum Metabolome of Moderate and Severe COVID-19 Patients Reflects Possible Liver Alterations Involving Carbon and Nitrogen Metabolism. Int. J. Mol. Sci. 2021;22:9548. doi: 10.3390/ijms22179548.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22179548</ArticleId><ArticleId IdType="pmc">PMC8431319</ArticleId><ArticleId IdType="pubmed">34502454</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmiedel B.J., Rocha J., Gonzalez-Colin C., Bhattacharyya S., Madrigal A., Ottensmeier C.H., Ay F., Chandra V., Vijayanand P. COVID-19 Genetic Risk Variants Are Associated with Expression of Multiple Genes in Diverse Immune Cell Types. Nat. Commun. 2021;12:6760. doi: 10.1038/s41467-021-26888-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26888-3</ArticleId><ArticleId IdType="pmc">PMC8604964</ArticleId><ArticleId IdType="pubmed">34799557</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasan M., Murtaz S.B., Islam M.U., Sadeq M.J., Uddin J. Robust and Efficient COVID-19 Detection Techniques: A Machine Learning Approach. PLoS ONE. 2022;17:e0274538. doi: 10.1371/journal.pone.0274538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0274538</ArticleId><ArticleId IdType="pmc">PMC9477266</ArticleId><ArticleId IdType="pubmed">36107971</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Chen D., Yuan D., Lausted C., Choi J., Dai C.L., Voillet V., Duvvuri V.R., Scherler K., Troisch P., et al. Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19. Cell. 2020;183:1479&#x2013;1495.e20. doi: 10.1016/j.cell.2020.10.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.037</ArticleId><ArticleId IdType="pmc">PMC7598382</ArticleId><ArticleId IdType="pubmed">33171100</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes E., Wist J., Masuda R., Lodge S., Nitschke P., Kimhofer T., Loo R.L., Begum S., Boughton B., Yang R., et al. Incomplete Systemic Recovery and Metabolic Phenoreversion in Post-Acute-Phase Nonhospitalized COVID-19 Patients: Implications for Assessment of Post-Acute COVID-19 Syndrome. J. Proteome Res. 2021;20:3315&#x2013;3329. doi: 10.1021/acs.jproteome.1c00224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.1c00224</ArticleId><ArticleId IdType="pubmed">34009992</ArticleId></ArticleIdList></Reference><Reference><Citation>Bizkarguenaga M., Bruzzone C., Gil-Redondo R., SanJuan I., Martin-Ruiz I., Barriales D., Palacios A., Pasco S.T., Gonz&#xe1;lez-Valle B., La&#xed;n A., et al. Uneven Metabolic and Lipidomic Profiles in Recovered COVID-19 Patients as Investigated by Plasma NMR Metabolomics. NMR Biomed. 2022;35:e4637. doi: 10.1002/nbm.4637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/nbm.4637</ArticleId><ArticleId IdType="pmc">PMC8646702</ArticleId><ArticleId IdType="pubmed">34708437</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghini V., Meoni G., Pelagatti L., Celli T., Veneziani F., Petrucci F., Vannucchi V., Bertini L., Luchinat C., Landini G., et al. Profiling Metabolites and Lipoproteins in COMETA, an Italian Cohort of COVID-19 Patients. PLoS Pathog. 2022;18:e1010443. doi: 10.1371/journal.ppat.1010443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010443</ArticleId><ArticleId IdType="pmc">PMC9022834</ArticleId><ArticleId IdType="pubmed">35446921</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorg A.-L., Bergfeld L., Jank M., Corman V., Semmler I., Goertz A., Beyerlein A., Verjans E., Wagner N., Von Bernuth H., et al. Cross-Sectional Seroprevalence Surveys of SARS-CoV-2 Antibodies in Children in Germany, June 2020 to May 2021. Nat. Commun. 2022;13:3128. doi: 10.1038/s41467-022-30482-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30482-6</ArticleId><ArticleId IdType="pmc">PMC9170697</ArticleId><ArticleId IdType="pubmed">35668073</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasan M.R., Suleiman M., P&#xe9;rez-L&#xf3;pez A. Metabolomics in the Diagnosis and Prognosis of COVID-19. Front. Genet. 2021;12:1358. doi: 10.3389/fgene.2021.721556.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2021.721556</ArticleId><ArticleId IdType="pmc">PMC8343128</ArticleId><ArticleId IdType="pubmed">34367265</ArticleId></ArticleIdList></Reference><Reference><Citation>Amberg A., Riefke B., Schlotterbeck G., Ross A., Senn H., Dieterle F., Keck M. Methods in Molecular Biology. Volume 1641 Springer; Berlin/Heidelberg, Germany: 2017. NMR and MS Methods for Metabolomics.</Citation><ArticleIdList><ArticleId IdType="pubmed">28748468</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa Dos Santos Junior G., Pereira C.M., Kelly Da Silva Fidalgo T., Valente A.P. Saliva NMR-Based Metabolomics in the War against COVID-19. Anal. Chem. 2020;92:15688&#x2013;15692. doi: 10.1021/acs.analchem.0c04679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.0c04679</ArticleId><ArticleId IdType="pubmed">33215503</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruzzone C., Gil-Redondo R., Seco M., Barrag&#xe1;n R., de la Cruz L., Cannet C., Sch&#xe4;fer H., Fang F., Diercks T., Bizkarguenaga M., et al. A Molecular Signature for the Metabolic Syndrome by Urine Metabolomics. Cardiovasc. Diabetol. 2021;20:155. doi: 10.1186/s12933-021-01349-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-021-01349-9</ArticleId><ArticleId IdType="pmc">PMC8320177</ArticleId><ArticleId IdType="pubmed">34320987</ArticleId></ArticleIdList></Reference><Reference><Citation>Loo R.L., Lodge S., Kimhofer T., Bong S.H., Begum S., Whiley L., Gray N., Lindon J.C., Nitschke P., Lawler N.G., et al. Quantitative In-Vitro Diagnostic NMR Spectroscopy for Lipoprotein and Metabolite Measurements in Plasma and Serum: Recommendations for Analytical Artifact Minimization with Special Reference to COVID-19/SARS-CoV-2 Samples. J. Proteome Res. 2020;19:4428&#x2013;4441. doi: 10.1021/acs.jproteome.0c00537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.0c00537</ArticleId><ArticleId IdType="pubmed">32852212</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitschke P., Lodge S., Kimhofer T., Masuda R., Bong S.-H., Hall D., Sch&#xe4;fer H., Spraul M., Pompe N., Diercks T., et al. J-Edited DIffusional Proton Nuclear Magnetic Resonance Spectroscopic Measurement of Glycoprotein and Supramolecular Phospholipid Biomarkers of Inflammation in Human Serum. Anal. Chem. 2022;94:1333&#x2013;1341. doi: 10.1021/acs.analchem.1c04576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.1c04576</ArticleId><ArticleId IdType="pubmed">34985268</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda R., Lodge S., Nitschke P., Spraul M., Schaefer H., Bong S.H., Kimhofer T., Hall D., Loo R.L., Bizkarguenaga M., et al. Integrative Modeling of Plasma Metabolic and Lipoprotein Biomarkers of SARS-CoV-2 Infection in Spanish and Australian COVID-19 Patient Cohorts. J. Proteome Res. 2021;20:4139&#x2013;4152. doi: 10.1021/acs.jproteome.1c00458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.1c00458</ArticleId><ArticleId IdType="pubmed">34251833</ArticleId></ArticleIdList></Reference><Reference><Citation>He B., Wang J., Wang Y., Zhao J., Huang J., Tian Y., Yang C., Zhang H., Zhang M., Gu L., et al. The Metabolic Changes and Immune Profiles in Patients with COVID-19. Front. Immunol. 2020;11:2075. doi: 10.3389/fimmu.2020.02075.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.02075</ArticleId><ArticleId IdType="pmc">PMC7485144</ArticleId><ArticleId IdType="pubmed">32983157</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H., Ma Q., Li C., Liu R., Zhao L., Wang W., Zhang P., Liu X., Gao G., Liu F., et al. Profiling Serum Cytokines in COVID-19 Patients Reveals IL-6 and IL-10 Are Disease Severity Predictors. Emerg. Microbes Infect. 2020;9:1123&#x2013;1130. doi: 10.1080/22221751.2020.1770129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1770129</ArticleId><ArticleId IdType="pmc">PMC7473317</ArticleId><ArticleId IdType="pubmed">32475230</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Li S., Liu J., Liang B., Wang X., Wang H., Li W., Tong Q., Yi J., Zhao L., et al. Longitudinal Characteristics of Lymphocyte Responses and Cytokine Profiles in the Peripheral Blood of SARS-CoV-2 Infected Patients. EBioMedicine. 2020;55:102763. doi: 10.1016/j.ebiom.2020.102763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102763</ArticleId><ArticleId IdType="pmc">PMC7165294</ArticleId><ArticleId IdType="pubmed">32361250</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudd P.A., Crawford J.C., Turner J.S., Souquette A., Reynolds D., Bender D., Bosanquet J.P., Anand N.J., Striker D.A., Martin R.S., et al. Distinct Inflammatory Profiles Distinguish COVID-19 from Influenza with Limited Contributions from Cytokine Storm. Sci. Adv. 2020;6:eabe3024. doi: 10.1126/sciadv.abe3024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abe3024</ArticleId><ArticleId IdType="pmc">PMC7725462</ArticleId><ArticleId IdType="pubmed">33187979</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray N., Lawler N.G., Zeng A.X., Ryan M., Bong S.H., Boughton B.A., Bizkarguenaga M., Bruzzone C., Embade N., Wist J., et al. Diagnostic Potential of the Plasma Lipidome in Infectious Disease: Application to Acute Sars-Cov-2 Infection. Metabolites. 2021;11:467. doi: 10.3390/metabo11070467.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/metabo11070467</ArticleId><ArticleId IdType="pmc">PMC8306636</ArticleId><ArticleId IdType="pubmed">34357361</ArticleId></ArticleIdList></Reference><Reference><Citation>Meoni G., Ghini V., Maggi L., Vignoli A., Mazzoni A., Salvati L., Capone M., Vanni A., Tenori L., Fontanari P., et al. Metabolomic/Lipidomic Profiling of COVID-19 and Individual Response to Tocilizumab. PLoS Pathog. 2021;17:e1009243. doi: 10.1371/journal.ppat.1009243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009243</ArticleId><ArticleId IdType="pmc">PMC7877736</ArticleId><ArticleId IdType="pubmed">33524041</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Xu E., Bowe B., Al-Aly Z. Long-Term Cardiovascular Outcomes of COVID-19. Nat. Med. 2022;28:583&#x2013;590. doi: 10.1038/s41591-022-01689-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorog D.A., Storey R.F., Gurbel P.A., Tantry U.S., Berger J.S., Chan M.Y., Duerschmied D., Smyth S.S., Parker W.A.E., Ajjan R.A., et al. Current and Novel Biomarkers of Thrombotic Risk in COVID-19: A Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nat. Rev. Cardiol. 2022;19:475&#x2013;495. doi: 10.1038/s41569-021-00665-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-021-00665-7</ArticleId><ArticleId IdType="pmc">PMC8757397</ArticleId><ArticleId IdType="pubmed">35027697</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Qin L., Zhang P., Li K., Liang L., Sun J., Xu B., Dai Y., Li X., Zhang C., et al. Longitudinal COVID-19 Profiling Associates IL-1RA and IL-10 with Disease Severity and RANTES with Mild Disease. JCI Insight. 2020;5:e139834. doi: 10.1172/jci.insight.139834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.139834</ArticleId><ArticleId IdType="pmc">PMC7406242</ArticleId><ArticleId IdType="pubmed">32501293</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgakis M.K., Van Der Laan S.W., Asare Y., Mekke J.M., Haitjema S., Schoneveld A.H., De Jager S.C.A., Nurmohamed N.S., Kroon J., Stroes E.S.G., et al. Monocyte-Chemoattractant Protein-1 Levels in Human Atherosclerotic Lesions Associate With Plaque Vulnerability. Arterioscler. Thromb. Vasc. Biol. 2021;41:2038&#x2013;2048. doi: 10.1161/ATVBAHA.121.316091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.121.316091</ArticleId><ArticleId IdType="pubmed">33827260</ArticleId></ArticleIdList></Reference><Reference><Citation>Jangra S., Ye C., Rathnasinghe R., Stadlbauer D., Alshammary H., Amoako A.A., Awawda M.H., Beach K.F., Berm&#xfa;dez-Gonz&#xe1;lez M.C., Chernet R.L., et al. SARS-CoV-2 Spike E484K Mutation Reduces Antibody Neutralisation. Lancet Microbe. 2021;2:e283&#x2013;e284. doi: 10.1016/S2666-5247(21)00068-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00068-9</ArticleId><ArticleId IdType="pmc">PMC8026167</ArticleId><ArticleId IdType="pubmed">33846703</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng X., Garcia-Knight M.A., Khalid M.M., Servellita V., Wang C., Morris M.K., Sotomayor-Gonz&#xe1;lez A., Glasner D.R., Reyes K.R., Gliwa A.S., et al. Transmission, Infectivity, and Neutralization of a Spike L452R SARS-CoV-2 Variant. Cell. 2021;184:3426&#x2013;3437.e8. doi: 10.1016/j.cell.2021.04.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.04.025</ArticleId><ArticleId IdType="pmc">PMC8057738</ArticleId><ArticleId IdType="pubmed">33991487</ArticleId></ArticleIdList></Reference><Reference><Citation>Begue F., Tanaka S., Mouktadi Z., Rondeau P., Veeren B., Diotel N., Tran-Dinh A., Robert T., V&#xe9;lia E., Mavingui P., et al. Altered High-Density Lipoprotein Composition and Functions during Severe COVID-19. Sci. Rep. 2021;11:2291. doi: 10.1038/s41598-021-81638-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-81638-1</ArticleId><ArticleId IdType="pmc">PMC7841145</ArticleId><ArticleId IdType="pubmed">33504824</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson J.K. Molecular Phenomic Approaches to Deconvolving the Systemic Effects of SARS-CoV-2 Infection and Post-Acute COVID-19 Syndrome. Phenomics. 2021;1:143&#x2013;150. doi: 10.1007/s43657-021-00020-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43657-021-00020-3</ArticleId><ArticleId IdType="pmc">PMC8295979</ArticleId><ArticleId IdType="pubmed">35233558</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng P., Zhu H., Witteles R.M., Wu J.C., Quertermous T., Wu S.M., Rhee J.W. Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty. Curr. Cardiol. Rep. 2020;22:34. doi: 10.1007/s11886-020-01293-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11886-020-01293-2</ArticleId><ArticleId IdType="pmc">PMC7189178</ArticleId><ArticleId IdType="pubmed">32350632</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>